<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Human Genome Sciences Inc. | Company News & Executive Profiles - HGSI | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/human+genome+sciences+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Human Genome Sciences Inc.]]></description>
	<s:counts start="0" returned="10" found="50" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Human Genome Sciences Begins Tumor Treatment Trial]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175357-human-genome-sciences-begins-tumor-treatment-trial%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Recently, Human Genome Sciences, Inc. HGSI and Aegera Therapeutics announced the initiation of dosing in a phase I clinical trial to evaluate the safety and tolerability of its lead inhibitor-of-apoptosis protein IAP, HGS1029, as monotherapy in patients with advanced lymphoid tumors. An additional phase I clinical...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 25 Nov 2009 12:30:36 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/human+genome+sciences+inc..html"><![CDATA[Human Genome Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HGSI</category>
		<category domain="tickers">HGSI</category>
	</item>
	<item>
		<title><![CDATA[Lower Third Quarter Loss for Human Genome]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F171504-lower-third-quarter-loss-for-human-genome%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Human Genome Sciences, Inc. HGSI reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a net loss of $74.2 million or 50 cents in the year ago quarter. The lower net loss for...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 05 Nov 2009 08:53:55 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/human+genome+sciences+inc..html"><![CDATA[Human Genome Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HGSI</category>
		<category domain="tickers">HGSI</category>
	</item>
	<item>
		<title><![CDATA[BREAKING NEWS: Groundbreaking lupus drug promising in second Phase III]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/breaking-news-groundbreaking-lupus-drug/18493/]]></link>
		<description><![CDATA[ Human Genome Sciences and its partner GlaxoSmithKline revealed that the high dose of their experimental lupus therapy demonstrated a statistically superior response compared to placebo in a second late-stage trial, laying the groundwork for an FDA marketing application.   Benlysta has helped transform HGS's prospects, and analysts were quick to...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 02 Nov 2009 05:56:09 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[Trial]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/human+genome+sciences+inc..html"><![CDATA[Human Genome Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HGSI</category>
		<category domain="tickers">GSK,HGSI</category>
	</item>
	<item>
		<title><![CDATA[Human Genome Sciences: Upgrade Precedes Data Report]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F169898-human-genome-sciences-upgrade-precedes-data-report%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Thursday morning, J.P. Morgan raised its rating on Human Genome Sciences HGSI to Overweight, two trading days ahead of Monday's much anticipated top-line data from the second Phase III trial evaluating Benlysta in lupus.  Previously, the firm had a neutral rating on the shares and a $14 target on...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 29 Oct 2009 11:30:09 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/the+inflection+point.html"><![CDATA[The Inflection Point]]></category>
		<category domain="http://resources.bnet.com/topic/human+genome+sciences+inc..html"><![CDATA[Human Genome Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HGSI</category>
		<category domain="tickers">HGSI</category>
	</item>
	<item>
		<title><![CDATA[BioMed News Bytes: Dyax, Human Genome Sciences, Aldagen]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F169841-biomed-news-bytes-dyax-human-genome-sciences-aldagen%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits:The BioMedReports.com FDA Calendar service includes a database with over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 29 Oct 2009 08:02:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/dyax+corp..html"><![CDATA[Dyax Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/human+genome+sciences+inc..html"><![CDATA[Human Genome Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DYAX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HGSI</category>
		<category domain="tickers">DYAX,HGSI</category>
	</item>
	<item>
		<title><![CDATA[FDA experts want to see more ABthrax data]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/fda-experts-abthrax-data/17896/]]></link>
		<description><![CDATA[ A panel of FDA experts says that Human Genome Sciences should provide more data on how its anthrax drug ABthrax stacks up against the antibiotics already available for treatment. HGS's studies underscored the effectiveness of antibiotics alone, raising questions about the need for adding ABthrax to the mix. The panel also...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Wed, 28 Oct 2009 07:58:43 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/expert.html"><![CDATA[expert]]></category>
		<category domain="http://resources.bnet.com/topic/panel.html"><![CDATA[panel]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/human+genome+sciences+inc..html"><![CDATA[Human Genome Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/antibiotics.html"><![CDATA[Antibiotics]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HGSI</category>
		<category domain="tickers">HGSI</category>
	</item>
	<item>
		<title><![CDATA[Human Genome Sciences' Options Attract Volatility Seller]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F164269-human-genome-sciences-options-attract-volatility-seller%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[optionMONSTER submits:  by David Russell   Options action in Human Genome Sciences HGSI surged 14-fold Wednesday as a volatility seller looked to earn premium from the drugmaker. by optionMONSTER]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 01 Oct 2009 04:52:34 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/optionmonster.html"><![CDATA[optionMONSTER]]></category>
		<category domain="http://resources.bnet.com/topic/human+genome+sciences+inc..html"><![CDATA[Human Genome Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HGSI</category>
		<category domain="tickers">HGSI</category>
	</item>
	<item>
		<title><![CDATA[Human Genome Sciences Jumps on Glaxo Takeover Rumors]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F158310-human-genome-sciences-jumps-on-glaxo-takeover-rumors%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Rumors of Glaxo's GSK takeover of Human Genome Sciences HGSI for $30/share have pushed the stock up considerably Tuesday. Human Genome Sciences stock was up $2.03 to $19.21 per share in afternoon trading with a gain of 11.79%. Aftermarket trading is up +0.46 to 19.66, another gain of 2.40%. I...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 26 Aug 2009 12:44:24 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/biopharma+investor.html"><![CDATA[BioPharma Investor]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/human+genome+sciences+inc..html"><![CDATA[Human Genome Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HGSI</category>
		<category domain="tickers">GSK,HGSI</category>
	</item>
	<item>
		<title><![CDATA[Human Genome Sciences Raises $310m on Huge Share Price]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F152818-human-genome-sciences-raises-310m-on-huge-share-price%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Carpe diem appears to be the motto of the day for Human Genome Sciences HGSI, which is taking advantage of the huge share price rise it has experienced since announcing positive phase III data for its lupus drug, Benlysta, and raising up to $310m in a share...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 31 Jul 2009 03:36:16 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/human+genome+sciences+inc..html"><![CDATA[Human Genome Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HGSI</category>
		<category domain="tickers">HGSI</category>
	</item>
	<item>
		<title><![CDATA[At Long Last, A Win Against Lupus: HGSI Succeeds in Phase III]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003240/at-long-last-a-win-against-lupus-hgsi-succeeds-in-phase-iii/]]></link>
		<description><![CDATA[Lupus is like the Black Knight in Monty Python and the Holy Grail: itâ€™s been telling drug developers for decades that â€œnone shall passâ€ -- and when they insist on trying to cross that Phase III bridge, well, then they must die. Until this week, when Human Genome Sciences came...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Wed, 22 Jul 2009 20:24:15 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/human+genome+sciences+inc..html"><![CDATA[Human Genome Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/lupus.html"><![CDATA[Lupus]]></category>
		<category domain="http://resources.bnet.com/topic/trista+morrison.html"><![CDATA[Trista Morrison]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HGSI</category>
		<category domain="tickers">HGSI</category>
	</item>
</channel>
</rss>
